Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : Applied Materials No-Politics Thread (AMAT) -- Ignore unavailable to you. Want to Upgrade?

To: Proud_Infidel who wrote (7834)	10/29/2003 3:45:50 PM
From: Big Bucks	Read Replies (1) \| Respond to of 25522

Brian...I think this will spook many investors in J&J and their stent technology supporting companies because of the potential for litigation and multi-million dollar settlements.... I think the analyst is disregarding this as an issue....

To: Proud_Infidel who wrote (7834)	10/29/2003 4:48:58 PM
From: Ian@SI	Read Replies (1) \| Respond to of 25522

OT: RE JNJ, FDA, and reporters. 1. The new JNJ stent has been used in several 100 thousands of patients. 2. Incidents, while greater in number, are no larger than seen during the clinical trials which led to the stent's approval. 3. Patients being treated have life threatoning illnesses. Some of them die, even with the best treatments. With the JNJ stent, fewer patients suffer the same condition and require another treatment. [More than 30% without the stent, less than 10% with the new stent] As much as I hate to do it, in this case, the analyst is probably right, the FDA is just doing its job, and the reporter has her head where the sun doesn't shine.

To: Proud_Infidel who wrote (7834)	10/29/2003 6:42:10 PM
From: rhering	Read Replies (1) \| Respond to of 25522

Brian, I guess the truth is not to pay much attention to any particular analyst unless you know the guy has a good understanding of the industry and does his homework. But, if you have a large position in a security, a bad analyst can cause you significant short term pain. The market tends to take at face value their misleading and downright incorrect statements, particularly if they come from one of the larger brokerage houses. It used to be that "good" CEOs (like Morgan) offered some check on the process with straight forward communication with the analyst community. Now in the wake of the corporate scandals, litigation and regulations regarding "equal access" disclosure, CEOs are very reluctant to be candid, and we are simply left with the "we're cautiously optimistic speech" every quarter. Instead of opening up communications the net effect of the current regulations has been to shut effectively shut them down. We are then left with poorly informed analysts to spin the limited information they have, whichever way suits their interests. Thankfully in the long run the market figures it out correctly, but over the short run its annoying. Regards, Roger